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Abstract
The aim of this study is to determine the effects of Atorvastatin treatment, an inhibitor of 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase, in periodontal disease. Male Wistar albino rats were randomly divided into five groups of
ten rats each: (1) non-ligated treatment (NL), (2) ligature only (L), (3) ligature plus 1 mg/kg Atorvastatin daily for 10 days, (4)
ligature plus 5 mg/kg Atorvastatin daily for 10 days, and (5) ligature plus 10 mg/kg Atorvastatin daily for 10 days. Following
the treatment course, the periodontal tissue of the animals was analyzed by Measurement of alveolar bone loss,
Histopathology and immunohistochemistry to determine of the expression of COX-2, MMP-2, MMP9, and RANKL/RANK/
OPG. ELISA assay was used to quantitate the levels of IL-1b, IL-10, TNF-a, myeloperoxidase, malondialdehyde, and
glutathione. The periodontal group treated with 10 mg/kg of Atorvastatin (3.960.9 mm; p,0.05) showed reverse the
alveolar bone loss caused Experimental Periodontal Disease compared to (L) (7.0260.17 mm). The periodontal group
treated with 10 mg/kg of Atorvastatin showed a significant reduction in MPO and MDA (p,0.05) compared to ligature only
group (L). Similarly in this group, the levels of the proinflammatory cytokines IL-1b and TNF-a were significantly decreased
(p,0.05). Furthermore, MMP-2, MMP-9, RANKL/RANK, and COX-2 were all downregulated by Atorvastatin treatment, while
OPG expression was increased. The findings support a role of Atorvastatin for reducing the bone loss, inflammatory
response, oxidative stress, and expression of extracellular matrix proteins, while reducing RANK/RANKL and increase OPG in
periodontal disease.
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Introduction
Atorvastatin is a member of the statin class of inhibitors.
Through the inhibition of 3-hydroxy-3-methylglutaryl-coenzyme
A (HMG-CoA) reductase, statins have revolutionized the treat-
ment of hypercholesterolemia. The beneficial effects of HMG-
CoA reductase inhibitors are usually attributed to their ability to
reduce endogenous cholesterol synthesis. In addition to bleeding,
statins are responsible for a variety of biochemical alterations,
including a reduced accumulation of esterified cholesterol in
macrophages, an increase in endothelial NO synthetase, a
reduction of the inflammatory process, and an increased stability
of atherosclerotic plaques [1].
Studies investigating Atorvastatin have shown that its treatment
leads to significant reductions in the levels of proinflammatory
cytokines (TNF, IL-1 and IL-6) [2]. In another study, Atorvastatin
significantly decreased bone resorption markers, including levels of
serum IL-6 [3]. Atorvastatin also decreased COX-2 expression
within peripheral blood monocytes in patients with acute
myocardial infarction [4] and increased IL-10 levels in a dose-
dependent manner [5]. Atorvastatin has also been used to inhibit
metalloproteinases [6,7], osteoclastogenesis and bone destruction,
and the expression of the receptor activator of nuclear factor-
kappa B ligand (RANKL) [8].
It is yet unknown if Atorvastatin would be beneficial in a
complex tissue such as the periodontium. In periodontal disease,
increased inflammation and bone loss is modulated by the
proinflammatory cytokines Il-1, Il-6, and TNF-a [9,10]. These
inflammatory cytokines further activate the expression of metallo-
proteinases and RANKL, ultimately contributing to periodontal
bone loss [11]. The aim of the present study was to assess the
effects of Atorvastatin in the treatment of periodontal disease by
measuring levels of inflammation, antioxidants, matrix metallo-
proteinases, and bone markers after Atorvastatin treatment of rats
with periodontal disease.




Experiments were performed on male Wistar rats (180–220 g)
housed in standard conditions (12 h light/dark cycle and
2260,1uC), with ad libitum access to standard diet (Presence/
Evialis do Brasil Nutric¸a˜o Animal LTDA, Sa˜o Paulo) and water.
The experimental protocol for experimental procedures and
animal treatment was approved by the Animal Ethics Committee
(number 28/2012) of the Federal University of Rio Grande Norte.
Model for experimental periodontitis (EPD)
EPD was induced in rats under anaesthesia induced by
ketamine (70 mg/kg administered i.p., 10% Quetamina, VET-
NIL, Sa˜o Paulo) and xylazine (10 mg/kg adminstered i.p., 2%
Calmium, Sa˜o Paulo) by the placement of a sterile nylon thread
ligature (3-0; Polysuture, NP45330, Sa˜o Paulo) around the cervix
of the maxillary left second molar. Eleven days after the initial
treatment, the animals were euthanized with 20 mg/kg thiopental
(0.5 g Thiopentax, Crista´lia, Sa˜o Paulo).
Drug treatments
For treatments, Atorvastatin (Lipitor 20mg Pfizer, Sa˜o Paulo,
Brazil) was solubilized in distilled water (vehicle). All treatments
(Atorvastatin or vehicle) were given orally by gavage 1 h before
ligation (induction of EPD) and thereafter once daily for 10 days.
The animals were assigned randomly to the following five groups
(10 animal for group): (1) a non-ligated group that received Water
(NL), (2) a ligated group that received Water (L), (3) a ligated group
treated with 1 mg/kg Atorvastatin (1 mg/kg Atorvast), (4) a
ligated group a group treated with 5 mg/kg Atorvastatin (5 mg/kg
Atorvast), and (5) a ligated group a group treated with 10 mg/kg
Atorvastatin (10 mg/kg Atorvast).
Measurement of alveolar bone loss (ABL)
The excised maxillae were fixed in 10% neutral formalin for
24 h. Both maxillary halves were then defleshed and stained with
aqueous methylene blue (1%) to differentiate the bone from the
tooth. Measurements of bone loss were made along the axis of
each root surface of all molar teeth. Three recordings were made
for the first molar teeth (three roots each) and two recordings for
the second and third molar teeth (two roots earch).The total
alveolar bone loss was obtained by taking the sum of the
recordings from the buccal tooth surfaces and subtracting the
values of the right maxilla(un ligated control) from the left maxilla,
in millimetres [12]. Morphometric analysis of the alveolar bone
was performed with standardized digital photography (OLYM-
PUS SC30), and the distance (millimeters) was measured with
Image Software (analysis getIT 5.1). L group was used for baseline
comparison.
Histopathological analysis
The immunohistochemical analysis and the histological scores
of the periodontal tissues were conducted by two calibrated oral
pathologists. The sectioning was performed in the laboratoryof
Morphology and Oral Pathology and subsequently analyzed by
light microscopy in the Department of Morphology, UFRN.
Alveolar bone specimens were harvested, fixed in 10% neutral-
buffered formalin, and demineralized in 5% nitric acid. Following
these treatments, the specimens were dehydrated, embedded in
paraffin, and sectioned along the molars in a mesio-distal plane for
haematoxylin-eosin staining. Sections of 4-mm thickness, corre-
sponding to the area between the first and second molars where
the ligature had been placed, were evaluated by light microscopy
(406magnification). Parameters such as inflammatory cell influx
and the integrity of the alveolar bone and the cementum were
analysed by a histologist in a single-blind fashion and graded as
follows: A score of 0 indicates that inflammatory cell infiltration is
absent or sparse and is restricted to the region of the marginal
gingiva, and that the alveolar process and cementum are
preserved; a score of 1 indicates moderate cellular infiltration
(inflammatory cellular infiltration present on the entire gingival
insert), minor alveolar process resorption, and an intact cemen-
tum; a score of 2 indicates accentuated cellular infiltration
(inflammatory cellular infiltration present in the gingiva and in
the periodontal ligament), accentuated degradation of the alveolar
process, and partial destruction of the cementum; and a score of 3
indicates accentuated cellular infiltration, complete resorption of
the alveolar process, and severe destruction of the cementum [13].
Immunohistochemical analysis of COX-2, MMP-2, MMP-9,
RANK-L, RANK and OPG
Thin sections of periodontal tissue (4 mm) were obtained with a
microtome and were transferred to gelatine-coated slides. Each
tissue section was then deparaffinised and rehydrated. The
gingival and periodontal tissues slices were washed with 0.3%
Triton X-100 in phosphate buffer, were quenched with endoge-
nous peroxidase (3% hydrogen peroxide), and were incubated with
the following primary antibodies (purchased from Santa Cruz
Biotechnology) overnight at 4uC : cyclooxygenase-2 (COX-2),
1:400; matrix metalloproteinase MMP-2, 1:400; MMP-9, 1:400;
receptor activator of the NF-kB ligand (RANK-L), 1:400; receptor
activator of NF-kB (RANK), 1:400; osteoprotegerin (OPG), 1:400.
After the slices were washed with phosphate buffer, they were
incubated with a streptavidin-HRP-conjugated secondary anti-
body (Biocare Medical) for 30 minutes, and immunoreactivity to
COX-2, MMP-2, MMP-9, RANK, RANK-L, and OPG was
visualized using a colorimetric-based detection kit following the
protocol provided by the manufacturer (TrekAvidin-HRP La-
bel+Kit from Biocare Medical, DAKO, USA).
Myeloperoxidase (MPO) assay
The relative level of neutrophil activity in the gingival samples
was measured by assaying MPO. Gingival samples were harvested
as described above and stored at 270uC until required for the
assay. After homogenisation and centrifugation (20006 g for
20 min), MPO activity in these samples was determined by a
colorimetric method described previously [14]. The results were
reported as units of MPO per milligram of tissue.
Malonaldehyde (MDA) levels
To assess lipid peroxidation, MDA production was measured
with a thiobarbituric acid reaction in gingival tissue from the rats.
Gingival tissue homogenate (0.25 ml of 10% tissue prepared in
0.15 M KCl) was added to a thiobarbituric acid solution (1.5 ml of
1% H3PO4 and 500 ml of a 0.6% thiobarbituric acid aqueous
solution), and the mixture was placed in a water bath and heated
for 45 min at 100uC. Next, 2 ml of n-butanol P.A. was added, and
the mixture was homogenized and then centrifuged at 12,000 rpm
for 15 min at 4uC. The absorbance of the butanol layer was
measured at 520 nm (A1) and 535 nm (A2) (Genesys 10s UV-VIS,
THERMA Scientific, England) The concentration of malonalde-
hyde was calculated as (A2 – A1), expressed as nmol of MDA per
gram of gingival tissue.
Atorvastatin Treatment for Periodontitis
PLOS ONE | www.plosone.org 2 October 2013 | Volume 8 | Issue 10 | e75322
Glutathione (GSH) assay
GSH levels in gingival tissue were measured as a marker for
antioxidant activity. The gingival samples were removed and
stored at 270uC until required for the assay. Gingival tissue
homogenate (0.25 ml of a 5% tissue solution prepared in 0.02 M
EDTA) was added to 320 ml of distilled water and 80 ml of 50%
TCA. The samples were then centrifuged at 3000 rpm for 15 min
at 4uC. The supernatant (400 ml) was added to 800 ml of 0.4 M
Tris buffer at pH 8.9 and 20 ml of 0.01 M DTNB. The
absorbance of each sample was measured at 420 nm, and the
results were reported as units of MPO per milligram of tissue.
IL-1b, Il-10, and TNF-a assay
The gingival sample tissueswerestored at 270uC until required
for each assay. The tissue collected was homogenized and
processed as described by [15]. The levels of IL-1b, Il-10, and
TNF-a in the gingival samples were determined with an ELISA
commercial kit (R&D Systems, EUA) as described previously [16].
Briefly, micro titer plates were coated overnight at 4uC with
antibodies against mouseTNF-a, IL-1b, and Il-10. After the plates
were blocked, the samples and standards were added at various
dilutions in duplicate and incubated at 4uC for 24 h. The plates
were washed three times with buffer. The following antibodies
were then added to the wells:biotinylated sheep polyclonal anti-
TNF-a,anti-IL-1b, or anti-IL-10 (diluted 1:1000 with 1% BSA
assay buffer). After further incubation at room temperature for
1 h, the plates were washed, and 50 ml of avidin-HRP (diluted
1:5000) was added. The color reagent o-phenylenediamine (OPD;
50 ml) was added 15 min later, and the plates were incubated in
the dark at 37uC for 15–20 min. The enzyme reaction was
stopped with H2SO4, and absorbance was measured at 490 nm.
The resulting values were expressed in pg/ml.
Statistical analysis
The data are presented as means+standard error of the mean
(SEM) or as medians, where appropriate. Analysis of Variance
(ANOVA) followed by Bonferroni’s test was used to calculate the
means, and the Kruskal–Wallis test followed by Dunn’s test was
used to compare medians (GraphPad PRISM 5.0 Software). A P-
value of ,0.05 was considered to indicate a significant difference.
Results
Effect of Atorvastatin treatment on alveolar bone loss in
rats with EPD
Rats with EPD (L) showed a significant alveolar bone loss
compared to NL (NL=1.460.07 mm; L=7.0260.17 mm;
p,0.001). It was observed that treatment with Atorvastatin
10 mg/Kg reverse the alveolar bone loss caused by EPD (Atorv
10 mg/Kg 3.960.9; p,0.05) (Fig. 1). These data are shown in
Fig. 2.A, which shows the macroscopic aspects of NL group (SO)
with no resorption of the alveolar bone when compared to the L
group (EPD), where severe bone resorption with root exposure is
observed (Fig. 2B). Fig. 2C shows the macroscopic appearance of
periodontium subjected to EPD and treated with Atorvastatin
10 mg/kg, where decreased bone loss is observed. Rats treated
with low levels of Atorvastatin (1 mg/kg and 5 mg/kg) had no
significant differences inalveolar bone loss compared to the L
group (L= 7.0260.17 mm; Atorv 1 mg/kg= 6.960.1 mm; Atorv
5 mg/kg= 5.860.6 mm;p.0.05), as seen in Figure 1.
Figure 1. Effect of Atorvastatin treatment on alveolar bone loss
associated with experimental periodontitis Disease (EPD) in
rats. Values are expressed as means6 SEM (###p,0.001, *p,0.05;
determined with ANOVA and Tukey’stest).
doi:10.1371/journal.pone.0075322.g001
Figure 2. Clinical characteristics of teeth and periodontal
tissue. (A) Samples from the NL group, with no resorption of the
alveolar bone. (B) Samples from the L group, where severe bone
resorption with root exposure is observed (Arrows). (C) Samples from
the L group treated with Atorvastatin 10 mg/Kg, where decreased bone
resorption is observed (Arrows). Images were obtained at an original
magnification of 1.76.
doi:10.1371/journal.pone.0075322.g002
Figure 3. Microscopic analysis. (A) Normal periodontium and (B)
periodontium from a rat presenting with periodontitis (treated with
saline) showing alveolar bone and cementumresorption and inflamma-
tory cell infiltration. (C) Reduced inflammation and alveolar bone loss in
the periodontium of rats treated with Atorvastatin (10 mg/kg) for 10
days. Sections were stained with H&E. Microscopic original magnifica-
tion at 406. Scale bars = 100 mm. G=gingiva; PL = Periodontal ligament;
D = dentin; AB = alveolar bone; C = Cementum; a = increased bone loss
in AB; b = resorption of cementum; c = inflammatory process in PL and
intense destruction of collagen fibers in the PL; e = decreased
inflammation process in PL anddiscrete destruction ofcollagen fibers
in PL; f = decreasedbone loss in AB.
doi:10.1371/journal.pone.0075322.g003
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Table 1. Histological analysis of maxillae from rats presenting with periodontal disease, Natal, RN, 2013.
Normal PD ATOVAST1 mg/Kg ATOVAST5 mg/Kg ATOVAST10 mg/Kg
0 (0-0) 3 (3-3)* 3 (3-3)* 2 (2-3) 2(1-2)
*p,0.05.
doi:10.1371/journal.pone.0075322.t001
Figure 4. Histological analyses of (A–C) MMP-2, (D-F) MMP-9, (G–I) COX-2, (J–L) RANK, (M–O) RANK-L, and (P–R) OPG in periodontal
tissue of rats with periodontal disease. Rats subjected to saline are pictured in A, D, G, J, M, P; rats with periodontal disease are pictured in B, E,
H, K, N, Q; rats with periodontal disease and treated with Atorvastatin (10 mg/kg) are pictured in C, F, I, L, O, R. 1006 magnification, bar
scale = 100 mm.
doi:10.1371/journal.pone.0075322.g004
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Histopathological analysis
Rats with periodontal disease that were treated with a high dose
of Atorvastatin (10 mg/kg) had significantly less alveolar bone loss
then similar animals that were treated with a low dose of
Atorvastatin (1 mg/kg; p,0.05). As seen in Figure 3A, we detected
a discrete cellular infiltration (restricted within the gingival
margin), preserved alveolar process, and cementum in the rats
with periodontitis that were treated with high-dose Atorvastatin for
10 days. This group also had a reduced level of inflammation and
alveolar bone loss in their periodontium.
A histological analysis of the region between the first and second
molars of control animals was representative of the structure of a
normal periodontium, in that the gingiva, periodontal ligament,
alveolar bone, and cementum can all be observed (Figure 3).
Conversely, the histopathology of the periodontium of untreated
animals subjected to experimental periodontitis (L) revealed
inflammatory cell infiltration coupled with severe cementum and
alveolar process destruction (Figure 3B; Table 1) and received a
median score of 3. Animals with periodontitis that were treated
with a high dose of Atorvastatin showed reduced inflammatory
parameters (Figure 3C) and had a median score of 2 (range: 1–2;
Table 1).
Immunohistochemical detection of COX-2, MMP-2, MMP-
9, RANK-L, RANK, and OPG
The periodontium of untreated rats with experimental peri-
odontitis showed marked immune-staining for COX-2, MMP-2,
MMP-9, RANK-L, and RANK (Figures 4B, 4E, 4H, 4K, and 4N),
compared to normal rats treated with saline alone (Figures 4A, 4D,
4G, 4J, and 4M). Furthermore, the periodontium of rats with
periodontitis and treated with a high-dose of Atorvastatin had even
lower levels of COX-2, as well as MMP-2, MMP-9, RANK-L and
RANK (Figures 4C, 4F, 4I, 4L, and 4O). In comparison to control
animals, the staining for osteoprotegerin (OPG) was moderately
increased in the with periodontitis (L) and significantly increased in
the animals with periodontitis that were treated with a high dose of
Atorvastatin.
Reduction of the inflammatory response
The myeloperoxidase (MPO) activity in each group with
periodontal disease (L) was significantly increased in comparison
with the control group (NL; p,0.01). The group with periodontitis
that was treated with the high dose of Atorvastatin (10 mg/kg)
showed a significant reduction in the concentration of MPO
(p,0.01; Figure 5). The levels of the proinflammatory cytokines
IL-1b and TNF-a were also significantly decreased in this group
(p,0.05; Figure 6). The group treated with 1 mg/kg and 5 mg/kg
Figure 5. Levels of myeloperoxidase (MPO), malondialdehyde (MDA), and glutathione (GSH) in control animals with no ligature
(NL), animals with periodontal disease induced by a ligature and treated with saline (L), or animals with periodontal disease and
treated with 1, 5, or 10 mg/kg of Atorvastatin (#; * p,0.05;).
doi:10.1371/journal.pone.0075322.g005
Figure 6. Levels of IL-1b, Il-10, and TNF-a in normal control animals with no ligature (NL), animals with periodontal disease induced
by a ligature and treated with saline (L), or animals with periodontal disease and treated with 1, 5, or 10 mg/kg of Atorvastatin (#;
*p,0.05; **p,0.01; ***p,0.001).
doi:10.1371/journal.pone.0075322.g006
Atorvastatin Treatment for Periodontitis
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Atorvastatin had the same levels of MPO, IL-1b, and TNF-a
compared to the Lgroup (p.0.05) (Figure 5).
Reduction of oxidative stress
Compared to saline, treatment with a high dose of Atorvastatin
in animals with periodontal disease significantly reduced mal-
ondialdehyde (MDA) activity (p,0.001), treatment with 1 mg/kg
and 5 mg/kg Atorvastatin reduced the activity of MDA (p,0.05),
while glutathione (GSH) levels were increased, although not
statistically different (Figure 5).
Discussion
Indeed, the study that was utilized in this study is an animal
model where periodontitis is induced by the intraoral placement of
a nylon thread,making it a trauma-based periodontal disease
model [17]. The initial immune response in chronic periodontitis
occurs following colonization of the gingival sulcus by period-
ontopathic bacteria. The presence of the bacteria induces the
production of cytokines and chemokines by the gingival epithe-
lium. This results in the expression of adhesion molecules,
increased permeability of gingival capillaries and chemotaxis of
polymorphonuclear neutrophils through the junctional epithelium
and into the gingival sulcus. The specific cytokines and
chemokines produced by this initial response lead to a perivascular
T-cell/macrophage dominated inflammatory infiltrate in the
connective tissues. [18]. The primary mediators of periodontal
inflammation are prostaglandins (PG; mainly PGE2) and the
cytokines interleukin-1 (IL-1) and tumour necrosis factor alpha
(TNF-a). [19].
A study using an animal model of oral mucositis demonstrated
that Atorvastatin significantly reduced TNF-a and IL-1b levels
[20]. These same findings were observed in a model of rheumatoid
arthritis [21]. In this study, using a model of periodontal disease,
animals treated with 10 mg/kg of Atorvastatin also had reduced
levels of TNF-a and IL-1b. Atorvastatin’s anti-inflammatory
activity is evidenced by the reduced expression of COX-2 (an
important enzyme selectively induced in inflamed tissue) in the
periodontal tissue. The observed reduction in myeloperoxidase
levels further confirms the reduction of leukocyte migration in
treated animals. The outcomes related to the activity of
Atorvastatin suggest that periodontal disease development involves
an intricate signalling pathway that encompasses metalloprotei-
nase expression and proteins linked to bone activity. Animals
treated with 1 mg/kg and 5 mg/kg of Atorvastatin did not show
reduced bone loss, anti-inflammatory, and/or antioxidant activity,
possibly because the effects of Atorvastatin treatment are dose
dependant and only observed at 10 mg/kg.
Matrix metalloproteinases (MMPs) are zinc- and calcium-
dependent endopeptidases that function at a neutral pH. Fibrillar
collagens are the major components of periodontal extracellular
matrix and, during pathologic conditions, these collagens are
further cleaved by active gelatinases (MMP-2 and MMP-9) [22].
Our results demonstrate that a 10-day treatment of Atorvastatin
inhibited MMP-2 and MMP-9. This observation is very important
since both MMP-2 and MMP-9 are strongly expressed during the
acute phase of periodontitis (7–21 days) [23].
Another activity observed in the evolution of periodontal disease
is the bone remodelling process dependent on a balance between
the RANKL and OPG [24]. RANKL, a member of the TNFR
family, exists in both a soluble and a membrane-bound form and
its mRNA is expressed by osteoblastic lineage cells. RANKL
stimulates osteoclasts to differentiate and inhibits their apoptosis.
Furthermore, it binds to osteoclasts [25]. OPG, on the other hand,
is a physiological humoral regulator of osteoclast-mediated bone
resorption. OPG appears to function as a secreted tumour necrosis
factor receptor (TNFR)-related protein and as a regulator of bone
density, which can act locally and systemically by down-regulating
osteoclast maturation [26].
In the present study, the reduction of the expression of RANKL
in tissue after treatment with Atorvastatin, coupled with the strong
staining of OPG, in tissue. Host-modulatory therapies for
periodontitis, including the use of non-steroidal anti-inflammatory
drugs (NSAIDs), have been shown to prevent formation of
prostaglandins, prostacyclin, and thromboxane, due to a blockage
of cyclooxygenase (COX) enzyme. In periodontal diseases,
prostaglandin E2 has been extensively correlated with inflamma-
tion and bone resorption [27]. The side effects of NSAIDs, mainly
cardiovascular, limit its use [28]. Another two classes of drugs,
angiotensin II type 1 receptor (AT1) blocker [29] and b-blockers
[30], have been investigated for periodontal disease and also found
to reduce cytokine levels. These studies corroborate the results
found by our study pertaining to Atorvastatin. In the future, there
is a need to investigate the signaling pathways that are affected to
better understand how can interfere with bone loss.
In conclusion, in periodontal disease, we find that Atorvastatin
has anti-inflammatory activity, as indicated by reduced cytokine
expression, and stress oxidative. These findings were further
supported by a reduced expression of MMP-2 and MMP-9 in
tissue, coupled with an increase in OPG and a decrease in
RANKL -.
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